A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Trial Profile

A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2015

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms RESOLVE-2
  • Most Recent Events

    • 10 Nov 2015 Primary endpoint has been met. (Montgomery-Asberg Depression Rating Scale)
    • 10 Nov 2015 Results published online in the American Journal of Psychiatry.
    • 10 Nov 2015 Status changed from withdrawn prior to enrolment to completed, as reported in the American Journal of Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top